# US 2020/0347055 A1 · SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347055 A1
- Document ID: US20200347055A1
- Status: Published application
- Kind: A1
- Application number: 16/929,696
- Filed: 2020-07-15
- Published: 2020-11-05
- Earliest claimed: 2015-12-23
- Assignees: Neurocrine Biosciences, Inc.
- Applicants: Neurocrine Biosciences, Inc.
- Inventors: Kevin McGee; Bin-Feng Li
- Web page: https://patentgrep.com/patent/US20200347055A1

## CPC

- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.

## Claims

### Claim at position 1

-31. (canceled)

### Claim 32

A VMAT2 inhibitor that is (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) having an impurity profile comprising total impurities in an amount that is no greater than about 5% by weight.

### Claim 33 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises total impurities in an amount that is no greater than about 3% by weight.

### Claim 34 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises total impurities in an amount that is no greater than about 2.5% by weight.

### Claim 35 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises total impurities in an amount that is no greater than about 2% by weight.

### Claim 36 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises total impurities in an amount that is no greater than about 1.5% by weight.

### Claim 37 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises total impurities in an amount that is no greater than about 1% by weight.

### Claim 38 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises total impurities in an amount that is no greater than about 0.5% by weight.

### Claim 39 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises total impurities in an amount that is no greater than about 0.1% by weight.

### Claim 40 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises one or more impurities chosen from: (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol or a salt thereof, (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-aminopropanoate, and (S)-(2S,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate.

### Claim 41 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises (R)-(2R,3R,11bR)-3-isobutyl-9,10,11b-trimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate.

### Claim 42 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises 6,7-dimethoxy-3,4-dihydroisoquinoline.

### Claim 43 (depends on 32)

The VMAT2 inhibitor of claim 32, wherein the impurity profile comprises (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-7-oxo-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl-2-amino-3-methylbutanoate.

### Claim 44 (depends on 32)

The VMAT2 inhibitor of claim 32, having an impurity profile comprising one or more impurities chosen from metal-based impurities.

### Claim 45 (depends on 32)

The VMAT2 inhibitor of claim 32, having an impurity profile comprising one or more impurities chosen from dimethylamine, formaldehyde, ethyl chloride, and isopropyl chloride.

### Claim 46 (depends on 32)

The VMAT inhibitor of claim 32, wherein (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) has a weight loss on drying (LOD) of no greater than about 5% by weight.

### Claim 47 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 4% by weight.

### Claim 48 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 3% by weight.

### Claim 49 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 2% by weight.

### Claim 50 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 1% by weight.

### Claim 51 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 0.8% by weight.

### Claim 52 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 0.6% by weight.

### Claim 53 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 0.4% by weight.

### Claim 54 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 0.2% by weight.

### Claim 55 (depends on 46)

The VMAT2 inhibitor of claim 46, having a weight loss on drying (LOD) of no greater than about 0.1% by weight.

### Claim 56 (depends on 32)

A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 32 and a pharmaceutically acceptable carrier.

### Claim 57 (depends on 33)

A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 33 and a pharmaceutically acceptable carrier.

### Claim 58 (depends on 40)

A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 40 and a pharmaceutically acceptable carrier.

### Claim 59 (depends on 45)

A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 45 and a pharmaceutically acceptable carrier.

### Claim 60 (depends on 46)

A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 46 and a pharmaceutically acceptable carrier.

### Claim 61 (depends on 49)

A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 49 and a pharmaceutically acceptable carrier.
